Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Space Shuttle Atlantis returns from International Space Station with tenth scientific payload for Astrogenetix

Space Shuttle Atlantis returned from the International Space Station (ISS) landing at the Kennedy Space Center this morning with the tenth scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. Astrogenetix is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS National Laboratory Pathfinder Vaccine (NLP-V) missions.

27 May 2010

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today announced the completion of enrollment in a Phase 2a proof-of-concept trial for the treatment of impetigo.

25 May 2010

Family of EPA-registered disinfecting products to be launched

An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.

25 May 2010

Silver nanoparticles effective at killing all kinds of bacteria

Writing in the International Journal of Nanoparticles, Rani Pattabi and colleagues at Mangalore University, explain how blasting silver nitrate solution with an electron beam can generate nanoparticles that are more effective at killing all kinds of bacteria, including gram-negative species that are not harmed by conventional antibacterial agents.

25 May 2010

BinaxNOW PBP2a test to detect PBP2a in MRSA

AdvanDx today announced that it will offer the BinaxNOW PBP2a test from Inverness Medical Innovations, Inc. (Waltham, MA) to customers in the United States. The test provides rapid detection of the penicillin-binding protein 2a present in Methicillin-Resistant Staphylococcus aureus (MRSA) directly from S. aureus positive blood cultures.

24 May 2010

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial with Lytixar (LTX-109) for nasal decolonisation of MRSA.

24 May 2010

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Sorrento Therapeutics, Inc. today announced that it has received an Advanced Technology Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus infections, including methicillin-resistant S. aureus, by disrupting quorum sensing, a bacterial communication process essential to virulence.

21 May 2010

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Allergan, Inc. today announced that the United States Food and Drug Administration has approved ZYMAXID (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms; Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumonia.

20 May 2010

Final data from Open-Label studies of Cinryze in patients with HAE now available

ViroPharma Incorporated today announced the availability of final data from Open-Label studies of Cinryze (C1 Esterase Inhibitor [Human]) in preventing and treating attacks of hereditary angioedema on the U.S. National Institutes of Health's online clinical trial registry, www.clinicaltrials.gov.

18 May 2010

Inhibitex reports net loss of $4.8M for first-quarter 2010

Inhibitex, Inc. today announced its financial results for the first quarter ended March 31, 2010. The Company also announced that it has initiated a Phase I single ascending dose trial of INX-189, its lead HCV nucleotide polymerase inhibitor, in healthy volunteers under an Investigational New Drug application with the U.S. Food and Drug Administration.

14 May 2010

MIT featured in U.S. Equity News

Micro Identification Technologies, Inc., a leader in rapid bacterial identification, today announces it was recently featured in an editorial published by U.S. Equity News that covers the history of bacteria, its life threatening effects, and publicly traded companies leading the fight against harmful bacteria.

12 May 2010

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Today, the biotech-vaccine company Intercell AG announced its financial results for Q1 and presented an update on the Company's development programs.

11 May 2010

CrystalGenomics completes European Phase I SAD study of CG400549 antibiotic candidate

CrystalGenomics, Inc., a novel drug R&D company announced today that the Phase I SAD (Single Ascending Dose) study for its novel antibiotic candidate, CG400549, has been successfully completed in Europe.

11 May 2010

Intercell to acquire Cytos' platform technology for monoclonal antibody discovery

Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.

6 May 2010

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.

4 May 2010

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

GlycoVaxyn AG, a leader in the development of innovative bioconjugate vaccines, and Professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, announced today that they have received a USD 3.4 million NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine. S. aureus is a major cause of hospital-based infections.

4 May 2010

miacom diagnostics announces new tests for faster diagnosis of sepsis

"Conventional PCR tests (PCR is short for polymerase chain reaction, a highly sensitive method of detecting nucleic acids) require several hours to produce a result. lucesco Bacteremia IVD panels are not only much faster with a result after only 30 minutes, they are also much more cost-efficient.

29 Apr 2010

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.

27 Apr 2010

International Day for Fighting Infection focuses on hospital infection control

Hospital acquired infections are the focus for the 3rd International Day for Fighting Infection, being marked on St. George’s Day, as experts meet to look at the evolution of infection control in hospitals.

22 Apr 2010

MRSA infections on the rise in hospitals and health care settings: AHRQ report

Despite activities to identify and reduce the spread of methicillin-resistant Staphylococcus aureus (MRSA) and other health care-associated infections in hospitals and health care settings nationwide, new reports released by the Agency for Healthcare Research and Quality show that MRSA is on the rise and continues to pose an alarming threat.

22 Apr 2010

Staphylococcus aureus News and Research

Further Reading

Space Shuttle Atlantis returns from International Space Station with tenth scientific payload for Astrogenetix

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

Family of EPA-registered disinfecting products to be launched

Silver nanoparticles effective at killing all kinds of bacteria

BinaxNOW PBP2a test to detect PBP2a in MRSA

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Final data from Open-Label studies of Cinryze in patients with HAE now available

Inhibitex reports net loss of $4.8M for first-quarter 2010

MIT featured in U.S. Equity News

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

CrystalGenomics completes European Phase I SAD study of CG400549 antibiotic candidate

Intercell to acquire Cytos' platform technology for monoclonal antibody discovery

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

miacom diagnostics announces new tests for faster diagnosis of sepsis

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

International Day for Fighting Infection focuses on hospital infection control

MRSA infections on the rise in hospitals and health care settings: AHRQ report

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News